Literature DB >> 28235950

The mast cell-B cell axis in lung vascular remodeling and pulmonary hypertension.

Siegfried Breitling1,2, Zhang Hui3, Diana Zabini1, Yijie Hu1, Julia Hoffmann3, Neil M Goldenberg1, Arata Tabuchi1,3, Roland Buelow4, Claudia Dos Santos1, Wolfgang M Kuebler5,3,6,7.   

Abstract

Over past years, a critical role for the immune system and, in particular, for mast cells in the pathogenesis of pulmonary hypertension (PH) has emerged. However, the way in which mast cells promote PH is still poorly understood. Here, we investigated the mechanisms by which mast cells may contribute to PH, specifically focusing on the interaction between the innate and adaptive immune response and the role of B cells and autoimmunity. Experiments were performed in Sprague-Dawley rats and B cell-deficient JH-KO rats in the monocrotaline, Sugen/hypoxia, and the aortic banding model of PH. Hemodynamics, cell infiltration, IL-6 expression, and vascular remodeling were analyzed. Gene array analyses revealed constituents of immunoglobulins as most prominently regulated mast cell-dependent genes in the lung in experimental PH. IL-6 was shown to link mast cells to B cells, as 1) IL-6 was upregulated and colocalized with mast cells and was reduced by mast-cell stabilizers and 2) IL-6 or mast cell blockade reduced B cells in lungs of monocrotaline-treated rats. A functional role for B cells in PH was demonstrated in that either blocking B cells by an anti-CD20 antibody or B-cell deficiency in JH-KO rats attenuated right ventricular systolic pressure and vascular remodeling in experimental PH. We here identify a mast cell-B cell axis driven by IL-6 as a critical immune pathway in the pathophysiology of PH. Our results provide novel insights into the role of the immune system in PH, which may be therapeutically exploited by targeted immunotherapy.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  B cells; inflammation; mast cells; pulmonary hypertension

Mesh:

Substances:

Year:  2017        PMID: 28235950     DOI: 10.1152/ajplung.00311.2016

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  21 in total

Review 1.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

3.  Update in Pulmonary Vascular Disease 2016 and 2017.

Authors:  Evan L Brittain; Thennapan Thennapan; Bradley A Maron; Stephen Y Chan; Eric D Austin; Edda Spiekerkoetter; Harm J Bogaard; Christophe Guignabert; Roxane Paulin; Roberto F Machado; Paul B Yu
Journal:  Am J Respir Crit Care Med       Date:  2018-07-01       Impact factor: 21.405

Review 4.  A pro-con debate: current controversies in PAH pathogenesis at the American Thoracic Society International Conference in 2017.

Authors:  Wolfgang M Kuebler; Mark R Nicolls; Andrea Olschewski; Kohtaro Abe; Marlene Rabinovitch; Duncan Stewart; Stephen Y Chan; Nicholas W Morrell; Stephen L Archer; Edda Spiekerkoetter
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-06-07       Impact factor: 5.464

5.  How does inflammation contribute to pulmonary hypertension?

Authors:  Rahul Kumar; Brian Graham
Journal:  Eur Respir J       Date:  2018-01-25       Impact factor: 16.671

6.  Targeting inflammation and immunity in pulmonary arterial hypertension: any easier after the CANTOS proof-of-concept that anti-inflammation cuts cardiovascular events?

Authors:  Christian Gerges; Irene Lang
Journal:  Pulm Circ       Date:  2018-01-08       Impact factor: 3.017

Review 7.  Inflammatory Mediators Drive Adverse Right Ventricular Remodeling and Dysfunction and Serve as Potential Biomarkers.

Authors:  Akylbek Sydykov; Argen Mamazhakypov; Aleksandar Petrovic; Djuro Kosanovic; Akpay S Sarybaev; Norbert Weissmann; Hossein A Ghofrani; Ralph T Schermuly
Journal:  Front Physiol       Date:  2018-05-23       Impact factor: 4.566

8.  Focus on Early Events: Pathogenesis of Pulmonary Arterial Hypertension Development.

Authors:  Olga Rafikova; Imad Al Ghouleh; Ruslan Rafikov
Journal:  Antioxid Redox Signal       Date:  2019-07-02       Impact factor: 8.401

9.  Hypoxic mast cells accelerate the proliferation, collagen accumulation and phenotypic alteration of human lung fibroblasts.

Authors:  Xiang Wang; Lianjun Lin; Xiaoyu Chai; Yanping Wu; Yong Li; Xinmin Liu
Journal:  Int J Mol Med       Date:  2019-11-11       Impact factor: 4.101

10.  Inflammation and autoimmunity in pulmonary hypertension: is there a role for endothelial adhesion molecules? (2017 Grover Conference Series).

Authors:  Wolfgang M Kuebler; Sébastien Bonnet; Arata Tabuchi
Journal:  Pulm Circ       Date:  2018-02-26       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.